MGAT5 alters the severity of multiple sclerosis

B Brynedal; J Wojcik; F Esposito; V Debailleul; J Yaouanq; F Martinelli-Boneschi; G Edan; G Comi; J Hillert; H Abderrahim

doi:10.1016/j.jneuroim.2010.01.003

MGAT5 alters the severity of multiple sclerosis

J Neuroimmunol. 2010 Mar 30;220(1-2):120-4. doi: 10.1016/j.jneuroim.2010.01.003. Epub 2010 Feb 1.

Authors

B Brynedal¹, J Wojcik, F Esposito, V Debailleul, J Yaouanq, F Martinelli-Boneschi, G Edan, G Comi, J Hillert, H Abderrahim

Affiliation

¹ The MS research group, Center for Molecular Medicine CMM L8:00, Department of Clinical Neuroscience, Karolinska Institutet, 171 76 Stockholm, Sweden. boel.brynedal@ki.se

PMID: 20117844
DOI: 10.1016/j.jneuroim.2010.01.003

Abstract

Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 x 10(-6) and 1.5 x 10(-7)).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Cohort Studies
DNA Mutational Analysis
Disability Evaluation
Europe
Female
Genetic Markers / genetics
Genetic Predisposition to Disease / genetics*
Genetic Testing
Genetic Variation / genetics
Genome / genetics
Genome-Wide Association Study*
Genotype
Glycosylation
Humans
Male
Multiple Sclerosis / genetics*
Multiple Sclerosis / metabolism
Multiple Sclerosis / physiopathology
N-Acetylglucosaminyltransferases / genetics*
Nerve Tissue Proteins / genetics*
Oligonucleotide Array Sequence Analysis
Severity of Illness Index

Substances

Genetic Markers
Nerve Tissue Proteins
MGAT5B protein, human
N-Acetylglucosaminyltransferases